DNA testing firm 23andMe avoids bankruptcy with an announcement on 19 May 2025 that it will be bought by US biotechnology company Regeneron Pharmaceuticals for $256 million (approximately £192 million). Regeneron Pharmaceuticals plans to operate 23andMe and continue all consumer genome services as a wholly-owned company subsidiary. However, this continues to raise questions for 15 million users worldwide about what will happen to their genetic information?
